D-0151-2018 Class II Terminated
FDA drug recall D-0151-2018 was initiated by Pfizer Inc. on Oct 20, 2017 and is designated Class II. Reason for recall: SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent The recall status is terminated (terminated Jun 2, 2020). Affected quantity: 1972 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 10, 2018
- Initiation Date
- Oct 20, 2017
- Termination Date
- Jun 2, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1972 bottles
Product description
Zoloft (sertraline HCl) tablets 25 mg* 30-count bottle, Rx only, Distributed by Roerig Division of Pfizer Inc., NY, NY, 10017 NDC 0049-4960-30
Reason for recall
SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent
Distribution pattern
Nationwide in the USA
Code information
Lot: S84026
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0151-2018
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.